Biotech giant (NASDAQ: MRNA) made a name for itself in the past couple of years as it developed and marketed one of the most successful coronavirus vaccines. The money it generated from this success should be enough to fund its research and development.
However, while the pandemic isn't over, it is no longer a public health emergency, according to the World Health Organization. Demand for coronavirus vaccines has started to fall, affecting Moderna's revenue. Meanwhile, the company still has no other approved products, but its $47 billion market capitalization rivals that of well-established biotechs.
Is Moderna's stock worth considering, especially at current levels? Let's find out.
Source Fool.com